CD19 and BCMA CAR T-Cells is under clinical development by Shanghai Unicar-Therapy Bio-Medicine Technology and currently in Phase II for Leukemia. According to GlobalData, Phase II drugs for Leukemia have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CD19 and BCMA CAR T-Cells’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CD19 and BCMA CAR T-Cells overview

Gene therapies are under development for the treatment of acute leukemia with alloimmune-mediated platelet transfusion refractoriness. They are administered by the parenteral route. The therapeutic candidates comprise autologous T cells genetically modified to express chimeric antigen receptor (CAR), targeting cells expressing B lymphocyte antigen CD19 and B-cell maturation antigen (BCMA).

Shanghai Unicar-Therapy Bio-Medicine Technology overview

Shanghai Unicar-Therapy Bio-Medicine Technology., is a pharmaceutical company and a tumor immunotherapy technology developer. The company is headquartered China.

For a complete picture of CD19 and BCMA CAR T-Cells’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.